Latest News

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Reckitt...

AIREA plc's ( LON:AIEA ) stock was strong after they recently reported robust earnings. We did some analysis and think...

Harmonic (HLIT) is back in focus after TDF, a major French broadcast infrastructure operator, upgraded its nationwide terrestrial network using Harmonic’s XOS and ProStream X platforms, spotlighting the company’s media processing capabilities. See our latest analysis for Harmonic. Despite the TDF and KBRO wins and new sports streaming features, Harmonic’s recent momentum has been mixed, with a 30 day share price return of a 7.35% decline contrasting with a 1 year total shareholder return of...

Artivion’s recent Q4 results showed revenue rising 19.2% year on year, driven by strong growth in stent grafts, On-X products, and preservation services, but coming in just 0.8% below analyst expectations. Despite delivering solid full-year 2025 adjusted revenue and EBITDA growth, Artivion’s relatively weaker performance versus peer estimates raises questions about how much near-term momentum investors should expect. Next, we’ll examine how this slight quarterly revenue miss, despite strong...

In early April 2026, Roivant Sciences reported mixed clinical updates, including Priovant’s launch of a Phase 2b/3 brepocitinib trial in lichen planopilaris and Immunovant’s Phase 3 batoclimab thyroid eye disease studies not meeting their primary endpoint. The brepocitinib program now spans four late-stage indications and has Priority Review for dermatomyositis, underscoring Roivant’s emphasis on high-need autoimmune conditions despite setbacks for batoclimab. We’ll now examine how the...

In late March 2026, Teva Pharmaceutical Industries reported three biosimilar milestones, including US FDA approval of PONLIMSI (denosumab-adet) as a biosimilar to Prolia for all its osteoporosis-related indications, alongside FDA and EMA acceptance of filings for a proposed Xolair (omalizumab) biosimilar across its full label. These advances highlight Teva’s effort to broaden its higher-value biopharmaceutical portfolio, using biosimilars to complement its generics base and support its Pivot...

CPI Property Group (XTRA:O5G) just reported full year 2025 results, returning to a net profit of €185.6 million while revenue and sales softened, and occupancy reached 93% with €1.1b of property disposals completed. See our latest analysis for CPI Property Group. The latest earnings release and balance sheet moves appear to have steadied sentiment, with a 1.38% 1 day share price return. However, a 5.77% 90 day share price decline and a 9.82% 1 year total shareholder return decline suggest...

Recent comments from television host Jim Cramer, who questioned Western Union (WU) as a growth idea despite its dividend appeal, have put the stock back in focus after a roughly 6.5% move higher. See our latest analysis for Western Union. The recent 6.5% share price move and 1 day share price return of 2.96% come against a weaker backdrop, with a 30 day share price return of 10.21% and a 1 year total shareholder return of 4.4% and 5 year total shareholder return of 49.31%. This suggests...

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after reporting record quarterly net product revenue, raising full year revenue guidance, achieving its first GAAP profitability, and completing enrollment in several key clinical trials. See our latest analysis for Mirum Pharmaceuticals. The recent clinical and regulatory milestones appear to have fed into strong momentum, with a 90 day share price return of 20.62% and a 1 year total shareholder return of 124.05%. The current share price...

In March 2026, FTI Consulting, Inc. appointed Kelly Henney as Senior Managing Director and Australia Leader of its Information Governance, Privacy & Security practice within the Technology segment, based in Sydney. Her background in artificial intelligence governance, data privacy, and digital risk, combined with legal and banking experience, enhances FTI’s ability to advise clients on complex regulatory and compliance challenges. Next, we’ll examine how Henney’s artificial intelligence...

In March 2026, Flex LNG Ltd. announced a new time charter for the Flex Aurora with a Supermajor, securing a firm two-year term plus optional extensions that could keep the vessel employed through 2034 and lift the company’s total contract backlog to a minimum of 55 years, or up to 82 years if all options are used. This incremental charter backlog adds further revenue visibility at a time when the company has flagged potential revisions to its full-year 2026 guidance amid volatile LNG...

On March 18, 2026, Core Scientific, Inc. entered into an amendment to its Delayed-Draw Bridge Credit Agreement, increasing total term loan commitments by US$500.0 million to US$1.0 billion and drawing the full incremental amount on the closing date. This substantial expansion of borrowing capacity materially alters Core Scientific’s financial flexibility, potentially affecting how it funds high‑performance computing projects and manages its evolving capital structure. We’ll now examine how...

Why Phreesia’s latest guidance cut matters for investors Phreesia (PHR) has drawn fresh attention after issuing lower fiscal 2027 revenue guidance, tying the reset to weaker spending from pharmaceutical clients. The announcement triggered a sharp share price drop and several analyst downgrades. See our latest analysis for Phreesia. The lowered fiscal 2027 revenue outlook, combined with mixed fourth quarter results and analyst downgrades, has sharply shifted sentiment. A 7 day share price...

In late March 2026, investors reacted to easing geopolitical tensions and a broader relief rally as confidence improved around NextNav’s prospects for an FCC Notice of Proposed Rulemaking tied to its 5G-based terrestrial GPS backup system. This shift in sentiment highlights how progress toward a clearer regulatory path can become a central driver of interest in NextNav’s spectrum-backed positioning and timing platform. Now we’ll examine how growing optimism around the FCC regulatory...

Oil driven pullback puts BKV in focus The recent easing of U.S. Iran tensions pushed oil prices lower, dragging energy names with them as traders locked in gains after a strong run and technical gauges flagged oversold conditions across the sector. BKV (BKV) was caught in that macro driven move, with selling pressure tied less to company specific headlines and more to shifting sentiment toward oil and gas exposure in the short term. See our latest analysis for BKV. That macro volatility sits...

On March 30, 2026, Option Care Health expanded its revolving credit facility by US$450 million to US$850 million and increased its share repurchase authorization to US$1 billion, while reaffirming its 2026 guidance. The move strengthens liquidity and signals management’s confidence in cash generation, giving the company more flexibility to fund growth and return capital to shareholders. We’ll now examine how the expanded US$1 billion buyback authorization reshapes Option Care Health’s...

Kingspan Group plc ( ISE:KRX ) is about to trade ex-dividend in the next 4 days. The ex-dividend date generally occurs...

Readers hoping to buy Foxtons Group plc ( LON:FOXT ) for its dividend will need to make their move shortly, as the...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

The stock was sluggish on the back of Vistry Group PLC's ( LON:VTY ) recent earnings report. Along with the solid...

Ceres Power Holdings plc ( LON:CWR ) is possibly approaching a major achievement in its business, so we would like to...

Readers hoping to buy Forbo Holding AG ( VTX:FORN ) for its dividend will need to make their move shortly, as the stock...

Investors were disappointed by Delek Group Ltd.'s ( TLV:DLEKG ) latest earnings release. Our analysis has found some...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...